Call for Abstract

7th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs, will be organized around the theme “Hastening Progress in HIV-AIDS to the Globe”

STD-HIV AIDS 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in STD-HIV AIDS 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Classification
  • Track 1-2Epidemiology
  • Track 1-3Reservoirs, Latency and Reactivation
  • Track 1-4Kaposi Sarcoma
  • Track 1-5HIV/AIDS Pandemics
  • Track 2-1Pneumocystis jiroveci
  • Track 2-2Cytomegalovirus
  • Track 2-3Mycobacteria
  • Track 2-4Toxoplasmosis
  • Track 2-5Malignant Neoplasms
  • Track 3-1Epidemiology
  • Track 3-2Immune Profile
  • Track 3-3Disease Burden
  • Track 3-4Health System
  • Track 4-1Hormones and HIV
  • Track 4-2HIV Genomics
  • Track 4-3Behavioural aspects
  • Track 4-4Drugs on Pregnancy
  • Track 4-5Therapeutics and Vaccine development
  • Track 5-1Innate Resistance
  • Track 5-2Transmission
  • Track 5-3Mechanisms
  • Track 5-4Exposure and primary infections
  • Track 5-5Immune evasion of HIV
  • Track 7-1 Syphilis
  • Track 7-2Genital Herpes
  • Track 7-3Chlamydia
  • Track 7-4Human Papillomavirus (HPV)
  • Track 7-5Gonorrhea
  • Track 8-1Tuberculosis
  • Track 8-2Hepatitis B
  • Track 8-3Cryptococcosis
  • Track 8-4Multifocal leukoencephalopathy
  • Track 8-5Toxoplasmosis
  • Track 9-1Prevention and control
  • Track 9-2Vaccine development
  • Track 9-3Clinical Trials
  • Track 9-4HIV/AIDS stigma,Discrimination
  • Track 9-5Epidemiology and statics
  • Track 10-1Antiretroviral therapy
  • Track 10-2Pediatric HIV
  • Track 10-3prevention of parent-to-child transmission
  • Track 11-1HIV/AIDS Surveillance
  • Track 11-2 Benefits of Early HIV Testing and Diagnosis
  • Track 11-3Microbicides
  • Track 11-4Pre-Exposure Prophylaxis
  • Track 11-5Current Status of HIV Testing
  • Track 12-1Home testing
  • Track 12-2CD4 T cell count
  • Track 12-3Viral load (HIV RNA)
  • Track 12-4Drug resistance
  • Track 12-5Testing blood for the presence of antibodies
  • Track 13-1Trichomonas vaginalis
  • Track 13-2Genital warts
  • Track 13-3Vaginitis
  • Track 13-4Intestinal Parasites
  • Track 13-5Mycoplasma Genitalium
  • Track 14-1Pre-exposure prophylaxis
  • Track 14-2Post-exposure prophylaxis
  • Track 14-3Male circumcision
  • Track 14-4Using condom
  • Track 14-5without sharing the needles
  • Track 15-1Control the growth of the virus
  • Track 15-2Improve how well your immune system works
  • Track 15-3Slow or stop symptoms
  • Track 15-4Prevent transmission of HIV to others
  • Track 16-1Course of HIV disease
  • Track 16-2Diagnostic and monitoring tools
  • Track 16-3Co-Infections (including opportunistic infections)
  • Track 16-4Comorbidities and complications (including those related to ART)
  • Track 16-5Antiretroviral therapies in adults, pediatrics
  • Track 16-6Strategies and therapies
  • Track 16-7Clinical issues specific to gender
  • Track 16-8Clinical issues specific to paediatric and adolescent HIV
  • Track 16-9Clinical issues specific to key populations & vulnerable populations
  • Track 17-1 E coli
  • Track 17-2 Hepatitis A
  • Track 17-3Nontyphoidal Salmonella
  • Track 17-4Norovirus
  • Track 17-5 Shigella
  • Track 17-6 Salmonella Typhi
  • Track 18-1Detection
  • Track 18-2Antibody Test
  • Track 18-3Antigen Test
  • Track 18-4HIV p24 antigen
  • Track 18-5HIV NAAT
  • Track 18-6Seroconversion symptoms
  • Track 19-1HIV and ethics
  • Track 19-2HIV Treatment and Care
  • Track 19-3Stigmatisation and discrimination
  • Track 19-4Physical and Psychosocial Nursing Care
  • Track 19-5Confidentiality
  • Track 19-6Pre Exposure Prophylaxis
  • Track 20-1Nanoparticles
  • Track 20-2Antiretroviral therapy and Future Developments
  • Track 20-3Gene therapy
  • Track 20-4Potential applications
  • Track 20-5Antiretroviral Nanomedicines
  • Track 21-1Recent and upcoming advances
  • Track 21-2Eradication of HIV reservoirs
  • Track 21-3Developing new therapies
  • Track 21-4Advances and porospects